BOLT Bolt Biotherapeutics Inc.: Earnings per share for the last twelve months
Minimal geopolitical influence and US localization create a stable backdrop for Bolt Biotherapeutics (BOLT). The trailing twelve-month earnings per share demonstrates business dynamics, where -15.00 reflects the latest metric value. This complements the success in developing targeted antibody-drug conjugates alongside industry behemoths. A team of top researchers with full academic freedom further drives this development.
Analytical breakdowns and data insights for company Bolt Biotherapeutics Inc. (BOLT)
- current quotes and average value forecast:
- company stock capitalization data:
- shareholders' equity book value data:
- debt and liquidity data:
Total Debt to Capital Bolt Biotherapeutics|BOLT - Long-Term Liabilities to Capital|Short-Term Debt to Capital Bolt Bio|BOLT - Company Debts|Debt to Book Capitalization Ratio Bolt Biotherapeutics, Inc.|BOLT - Long-Term Debt|Company Short-Term Debt Bolt Biotherapeutics|Quick Liquidity Indicator boltbio.com
- earnings and valuation multiples indicators:
BOLT - Profit After Payment of Taxes|Future Profit Bolt Biotherapeutics|BOLT - Company Value to Net Income|Forward P/E Multiple Bolt Bio|BOLT - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Bolt Biotherapeutics, Inc.|BOLT - Operating income before deduction of amortization|Earnings per share for the last twelve months Bolt Biotherapeutics|BOLT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months boltbio.com|BOLT - Net earnings per one share growth for the current year|Earnings growth forecast for next year Bolt Biotherapeutics
- sales and revenue data:
Fundamental company valuation:BOLT - boltbio.com
A conservative investor evaluates Bolt Biotherapeutics (BOLT) through the lens of real earnings per share. This metric is calculated by dividing the total annual net income by the total number of outstanding securities. By analyzing the net income per share chart for the last 12 months on GURU.Markets, one can track the efficiency of grant utilization and partner payments. For the biotechnology sector, this indicator reflects the balance between immunotherapy development costs and current funding. The trend of this metric determines the risk level associated with long-term ownership of the asset.
Main competitors
ARGX - Earnings per share for the last twelve months|biontech.de (BNTX) - Net earnings per share for the last 12 months|Abivax Pharma (ABVX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months ADMA Biologics Inc|Net earnings per share for the last 12 months PTGX|Net earnings per share (EPS TTM) Immunovant Therapeutics|Earnings per share for the last twelve months Kiniksa Pharmaceuticals (KNSA)|grifols.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ADPT (Adaptive Biotechnologies Corporation)|Celldex Therapeutics Inc (CLDX) - Net earnings per one share for the last twelve months|Aurinia Pharma - Net earnings per share (EPS TTM)|BCRX: Earnings per share for the last twelve months|Vera Therapeutics, Inc. (VERA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months dianthustx.com (DNTH)|Earnings per share for the last twelve months Pharvaris|Earnings per share for the last twelve months ABCL|Net earnings per share for the last 12 months TRML (Tourmaline Corp)|Earnings per share for the last four quarters PGEN|Pharming Group N.V. - Net earnings per share for the last 12 months|Earnings per share for the trailing year NKTR|Upstream Bio - Net earnings per share (EPS TTM)|ZBIO: Earnings per share for the last twelve months|IMNM: Net earnings per share (EPS TTM)|GOSS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months KalVista Pharmaceuticals|Net earnings per one share for the last twelve months septerna.com SEPN|Net earnings per share for the last 12 months PVLA (Pieris Pharmaceuticals, Inc.)|Earnings per share for the last four quarters SVRA|Net earnings per share (EPS TTM) RIGL (Rigel Pharmaceuticals Inc)|Earnings per share for the trailing year ANAB|Astria Therapeutics - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months engene.com|RAPT Therapeutics, Inc. (RAPT) - Earnings per share for the last twelve months|Aerovate Therapeutics - Earnings per share for the trailing year|ACRS (Aclaris) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kyverna Therapeutics, Inc|Earnings per share for the last twelve months Tiziana Life Sciences (TLSA)|CABA: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) VTYX (Ventyx Biosciences, Inc.)|Theratechnologies, Inc. (THTX) - Net earnings per one share for the last twelve months|AVTX: Net earnings per share for the last 12 months|ELDN - Net earnings per share (EPS TTM)|AGEN (Agenus) - Net earnings per share for the last 12 months|CLYM: Earnings per share for the last four quarters|ZURA (Zura Bio Limited) - Net earnings per share (EPS TTM)|aTyr Pharma Inc (ATYR) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) ADAG|Net earnings per share for the last 12 months ikenaoncology.com IMA|Earnings per share for the last twelve months Shattuck Labs STTK|Net earnings per share for the last four quarters Equillium Inc (EQ)|Connect Pharma - Net earnings per share (EPS TTM)|IMUX: Earnings per share for the last twelve months|atarabio.com (ATRA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months InflaRx (IFRX)|Earnings per share for the last twelve months X4 Pharmaceuticals|Earnings per share for the last twelve months ACET|Net earnings per share for the last 12 months CELU (Celularity Inc.)|Earnings per share for the last four quarters INMB|Earnings per share for the last twelve months Barinthus Bio BRNS|KZR (Kezar Life Sciences Inc) - Earnings per one share for the last 12 months|SAB Biotherapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year AKTX (akaritx.com)|ENLV: Net earnings per share (EPS TTM)|Q32 Bio (QTTB) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months GeoVax Labs Inc|EDSA: Earnings per share for the trailing year|Earnings per share for the last twelve months iBio, Inc. (IBIO)|Net earnings per share for the last 12 months carismatx.com CARM|Net earnings per share (EPS TTM) XTLB (XTL Biopharmaceuticals Ltd.)|Net earnings per share (EPS TTM) HCW Biologics, Inc. HCWB|APVO: Net earnings per share for the last 12 months|Earnings per share for the trailing year AIM (AIM ImmunoTech, Inc.)|ADTX: Net earnings per share (EPS TTM)|GRI - Net earnings per share for the last four quarters|Earnings per share for the last twelve months XORTX Therapeutics|Net earnings per share for the last 12 months Vyome Holdings Inc. (HIND)|Earnings per share for the last twelve months Revelation Bio (REVB)|Net earnings per share for the last 12 months Indaptus Corp INDP|Scinai Immunotherapeutics - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) CalciMedica Inc CALI|AFMD - Earnings per share for the last twelve months|ALLK (Allakos Inc.) - Earnings per share for the last 12 months|HOOK: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months IGM Biosciences (IGMS)|ITOS (iTeos Therapeutics) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months OCEA|Earnings per share for the last twelve months TC BioPharm (TCBP)|THRD - Net earnings per one share for the last twelve months
